Hangzhou V-Onco Medical Technology Co., Ltd. is a high-tech company driven by clinical needs to innovate medical technology, dedicated to providing optimal medical solutions for clinical practice.

The company's core technology is based on its entirely self-developed irreversible electroporation (IRE) technology. Irreversible electroporation (IRE) tissue ablation technology offers significant advantages of being non-thermal and selective. It enables complete ablation of lesions while preserving the integrity of adjacent critical ductal structures, making it a cutting-edge tool for achieving "thorough lesion removal with minimal collateral damage." As such, it is recognized as the next-generation tissue ablation technology.

 V-Onco's R&D team is a pioneer and trailblazer in the theory and practice of tumor irreversible electroporation. Since first introducing the novel concept of using irreversible electroporation for tumor treatment internationally in 2000, the team has successively proposed and developed three generations of IRE technology, consistently leading the global advancement and iteration of IRE medical products.

"WKnife" is the culmination of the team's latest independent research and development achievements. It represents the newest generation of irreversible electroporation technology (SIRE) products, overcoming the limitations of traditional irreversible electroporation devices in terms of high anesthesia requirements, limited ablation range, and needle placement challenges. It eliminates the need for muscle relaxants, has no impact on the patient's heart rate, and enables safer, more efficient tissue or tumor ablation under local anesthesia or sedation.

The company focuses on the field of minimally invasive tumor ablation, aiming to organically integrate the latest minimally invasive medical technologies to propose optimal treatment approaches for patients. The goal is to help patients alleviate suffering, improve quality of life, and extend overall survival (OS).